This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

22 Biopharma Stocks With Breakout Potential in 2012

Celgene (CELG)
Drug/indication: Apremilast for psoriasis and psoriatic arthritis (phase III) and rheumatoid arthritis (phase II)
Top-line results expected in the second half of the year.
Achieving European approval for first-line use of Revlimid in multiple myeloma remains the most important catalyst for the stock in the remainder of 2012. After that, however, Celgene becomes a clinical trial story for the first time in awhile. As a pill, apremilast has the potential to take a bit out of the market share in psoriasis and rheumatoid arthritis now dominated by biologic injectable therapies.


Celsion (CLSN)
Drug/indication: Thermodox in liver cancer (phase III trial)
Top-line results expected in the fourth quarter
The "HEAT" study compares Thermodox plus radiofrequency thermal ablation (RFA) versus RFA alone in patients with primary liver cancer. The primary endpoint of the study is improvement in progression-free survival.
An interim analysis of the "HEAT" study was conducted in November 2011 but did not result in a patient benefit large enough to stop the study early.


ChemoCentryx (CCXI)
Drug/indication: CCX140 for diabetic nephropathy (phase II trials)
Top-line results expected in late fourth quarter 2012 but possibly early 2013
ChemoCentryx is conducting two phase II studies of CCX140 versus placebo in patients with diabetic nephropathy.


Clovis Oncology (CLVS)
Drug/indication: CO-101 for pancreatic cancer (phase III trial)
Top-line results expected in fourth quarter
The "LEAP" study compares CO-101 versus gemcitabine in metastatic, chemo-naive pancreatic cancer patients whose tumors express low levels of hENT1, a protein which gemcitabine requires to enter cells. Survival is the study's primary endpoint.


Eli Lilly (LLY)
Johnson & Johnson (JNJ), Pfizer (PFE), Elan (ELN)
Drugs/indication: Solanezumab and bapineuzumab for Alzheimer's disease. (phase III trials)
Expected top-line results: Second half 2012
Two different drugs in separate and large phase III clinical trial programs, but solanezumab and bapineuzumab are linked because both are antibodies designed to break up sticky clumps of protein known as amyloid beta that lodge in the brain and are believed to cause the memory problems which are the signal manifestation of Alzheimer's disease.
Lilly is conducting two, large phase III studies (EXPEDITION AND EXPEDITION II) of solanezumab in patients with mild to moderate Alzheimer's. The studies' primary endpoint is change or improvement in memory (cognition) and activities of daily loiving. Results from a previous phase II study showed no benefit for patients while a different but similar Lilly Alzheimer's drug, semegacestat, failed a phase III study in 2010. [Semegacestat-treated patients actually did worse than placebo.]
Johnson & Johnson is conducting four phase III studies of bapineuzumab, separated into North American and rest -of-world patients as well as patients who carry or don't carry the APOE4 gene, a marker for more aggressive and earlier-onset Alzheimer's. Primary endpoints are the same as those used in the solanezumab studies. A phase II study of bapineuzumab failed to demonstrate a benefit for Alzheimer's patients.


3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs